4//SEC Filing
Schreiber Taylor 4
Accession 0001193125-25-189087
CIK 0001680367other
Filed
Aug 26, 8:00 PM ET
Accepted
Aug 27, 6:30 AM ET
Size
8.3 KB
Accession
0001193125-25-189087
Insider Transaction Report
Form 4
Schreiber Taylor
DirectorChief Executive Officer
Transactions
- Award
Warrants (Right to Buy)
2025-08-25+25,610→ 25,610 totalExercise: $1.08→ Common Stock (25,610 underlying) - Award
Common Stock
2025-08-25$0.87/sh+25,610$22,222→ 96,612 total
Holdings
- 2,610,750(indirect: By LLC)
Common Stock
Footnotes (2)
- [F1]On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.
- [F2]The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.
Documents
Issuer
Shattuck Labs, Inc.
CIK 0001680367
Entity typeother
Related Parties
1- filerCIK 0001601942
Filing Metadata
- Form type
- 4
- Filed
- Aug 26, 8:00 PM ET
- Accepted
- Aug 27, 6:30 AM ET
- Size
- 8.3 KB